<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ENOXAPARIN <img border="0" src="../images/pr.gif"/></span><br/>(e-nox'a-pa-rin)<br/><span class="topboxtradename">Lovenox<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">low molecular weight heparin</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Low molecular weight heparin with antithrombotic properties. Does not affect PT. Does affect thrombin time (TT) and activated
         thromboplastin time (aPTT) up to 1.8 times the control value.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antithrombotic properties are due to its antifactor Xa and antithrombin (antifactor IIa) in the coagulation activities. An
         effective anticoagulation agent; used for prophylactic treatment as an antithrombotic agent following certain types of surgery.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of deep vein thrombosis (DVT) after hip, knee, or abdominal surgery, treatment of DVT and pulmonary embolism, management
         of acute coronary syndrome.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with active major bleeding, GI bleeding, hemophilia, heparin hypersensitivity, heparin-induced thrombocytopenia (HIT),
         thrombocytopenia associated with an antiplatelet antibody in the presence of enoxaparin, bleeding disorders, idiopathic thrombocytopenia
         purpura (ITP), hypersensitivity to enoxaparin; porcine protein hypersensitivity, neonates.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Uncontrolled arterial hypertension, recent history of GI disease, benzyl alcohol hypersensitivity, conditions or surgery with
         increased risk of bleeding, hepatic disease, hypertension, coagulopathy, thrombolytic therapy, thrombocytopenia, dental disease,
         dental work, diabetic retinopathy, dialysis, diverticulitis, inflammatory bowel disease, intramuscular injections, lumbar
         puncture, menstruation, obesity, peptic ulcer disease, older adults, endocarditis, renal disease, renal impairment, spinal
         anesthesia, stroke, surgery, pregnancy (category B), lactation. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of DVT after Hip or Knee Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 30 mg b.i.d. for 1014 d starting 1224 h post-surgery<br/><br/><span class="indicationtitle">Prevention of DVT after Abdominal Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 40 mg q.d. starting 2 h before surgery and continuing for 710 d (max: 12 d)<br/><br/><span class="indicationtitle">Treatment of DVT and Pulmonary Embolus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 1 mg/kg q12h or 1.5 mg/kg/d; monitor anti-Xa activity to determine appropriate dose<br/><br/><span class="indicationtitle">Acute Coronary Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 1 mg/kg q12h for 28 d, give concurrently with aspirin 100325 mg/d<br/><br/><span class="impairmenttitle">Adjustment for Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Use a TB syringe or prefilled syringe to ensure accurate dosage.</li>
<li>Do not expel the air bubble from the 30 or 40 mg prefilled syringe before injection.</li>
<li>Place patient in a supine position for injection of the drug.</li>
<li>Alternate injections between left and right anterolateral and posterolateral abdominal wall.</li>
<li>Hold the skin fold between the thumb and forefinger and insert the whole length of the needle into the skin fold. Hold skin
            fold throughout the injection. Do not rub site post injection.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergic reactions (rash, urticaria), fever, <span class="speceff-life">angioedema</span> arthralgia, pain and inflammation at injection site, peripheral edema, arthralgia, fever. <span class="typehead">Digestive:</span> Abnormal liver function tests. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Hemorrhage</span>
<i>,</i> thrombocytopenia, ecchymoses, anemia. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Aspirin, <span class="classification">nsaids</span>, <b>warfarin</b> can increase risk of hemorrhage. <span class="typehead"> Herbal:</span>
<b>Garlic,</b>
<b>ginger,</b>
<b>ginkgo,</b>
<b>feverfew,</b>
<b>horse chestnut</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 91% absorbed from SC injection site. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Duration:</span> 4.6 h. <span class="typehead">Distribution:</span> Appears to accumulate in liver, kidneys, and spleen. Does not cross placenta. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 4.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline coagulation studies; periodic CBC, platelet count, urine and stool for occult blood.</li>
<li>Monitor platelet count closely. Withhold drug and notify physician if platelet count less than 100,000/mm<sup>3</sup>.
         </li>
<li>Monitor closely patients with renal insufficiency and older adults who are at higher risk for thrombocytopenia.</li>
<li>Monitor for and report immediately any sign or symptom of unexplained bleeding.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician promptly signs of unexplained bleeding such as: pink, red, or dark brown urine; red or dark brown vomitus;
            bleeding gums or bloody sputum; dark, tarry stools.
         </li>
<li>Do not take any OTC drugs without first consulting physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>